GCTK Company Profile and Key Details

GlucoTrack, Inc. generated EPS of -$1,359.65 over the past year. Five-year average earnings growth is -18.33%.

GlucoTrack, Inc. has 6.56 million shares outstanding. The public float is 6.20 million shares, elevated short interest at 36.48% of float. This equals 2.39 million shares. The short ratio is 0.4 days. Institutional investors hold 4.42% of the float. Insiders own 15.78%. SYCOFF DREW holds 138.00 thousand shares, John A. Ballantyne Revocable Living Trust dated 08/01/2017 has 59.26 thousand shares and BALLANTYNE JOHN has 59.26 thousand shares.

GlucoTrack, Inc. (NASDAQ:GCTK) closed at $0.48 USD, losing -$0.30 (-38.85%) from the previous close of $0.78. The stock is currently mid-range between its 52-week high and low $0.25 and $14.14. With a market capitalization of about $270.68 thousand, GlucoTrack, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.76). Key stats such as the average daily volume over the past year has been around 11.64 million shares, trading with heavier-than-usual volume. Headquartered in Rutherford, NJ, GlucoTrack, Inc. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Paul V. Goode, the company employs approximately 15 people and listed since April 25, 2013. Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems.

GCTK has shown mixed momentum, losing -0.52% over the past week and -42.94% over the past quarter, though year-to-date performance is down -1.81%. Short-term trend indicators are bullishly aligned (SMA20 -4.4%, SMA50 -47.17%, SMA200 -70.99%). The stock’s 14-day RSI is 29.89 (weak momentum), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -94.62% below its high and over 13.89% above its low. Average 10-day trading volume of 48.88 million shares is significantly above the 3-month average of 10.74 million, indicating heightened recent market interest.

GlucoTrack, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $14.39. This means the shares are trading below this model’s fair value.

GlucoTrack, Inc. trades at a P/E ratio of -0.08, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.92 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.02, also above market averages.

GlucoTrack, Inc. (NASDAQ:GCTK) shares are flat -1.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows GlucoTrack, Inc. trading at a premium to the broader market with a P/E of -0.08. Our AI forecast model points to short-term strength (27.88% over two weeks), a medium-term rise (34.17% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that GlucoTrack, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 27.88%, with price expected at $0.61 by August 14, 2026, within a range of $0.51 to $0.70 3-Month Outlook: Projected rise of 34.17%, reaching $0.64 by October 29, 2026, with a range of $0.00 to $2.66. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by July 30, 2027, within a range of $0.00 to $69.94.